Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients

Abstrakt

Here, we report seven adult STAT1 GOF patients (two with novel mutations) with an uneventful course of COVID-19 vaccination, and/or SARS-CoV-2 infection, including two patients receiving JAK inhibitor ruxolitinib.

Klíčová slova

• COVID-19
• mRNA Vaccine
• STAT1 GOF Patients